Good morning :)
Place Order
Add to Watchlist

Sanofi Consumer Healthcare India Ltd

SANOFICONR Share Price

5,009.801.66% (-84.50)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹11,537 cr, stock is ranked 483

Stock is 1.27x as volatile as Nifty

SANOFICONR Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹11,537 cr, stock is ranked 483

Stock is 1.27x as volatile as Nifty

SANOFICONR Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
68.5642.26
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.446.450.86%

SANOFICONR Analyst Ratings & Forecast

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

SANOFICONR Company Profile

Sanofi Consumer Healthcare India Ltd produces and markets a wide range of consumer healthcare products, including pharmaceuticals and nutritional products.

SANOFICONR Similar Stocks (Peers)

Compare with peers 
PE Ratio
36.96
1Y Return
12.61%
Buy Reco %
88.24
PE Ratio
22.73
1Y Return
0.33%
Buy Reco %
75.00
PE Ratio
56.23
1Y Return
17.89%
Buy Reco %
72.00
PE Ratio
18.10
1Y Return
4.29%
Buy Reco %
53.33
PE Ratio
50.42
1Y Return
15.83%
Buy Reco %
81.25
Compare with Peers

SANOFICONR Forecasts

SANOFICONR Forecast

Price

Revenue

Earnings

SANOFICONR

Income

Balance Sheet

Cash Flow

SANOFICONR Income Statement

Loading...

Financial YearFY 2023FY 2024TTM
Total Revenue559.50737.50682.80
Raw Materialssubtract156.40169.50443.20
Power & Fuel Costsubtract0.200.10
Employee Costsubtract54.40102.70
Selling & Administrative Expensessubtract79.40104.30
Operating & Other expensessubtract48.00105.70
Depreciation/Amortizationsubtract1.804.505.60
Interest & Other Itemssubtract0.003.904.30
Taxes & Other Itemssubtract54.4065.8061.40
EPS824.50144.6273.08
DPS0.000.000.00
Payout ratio0.000.000.00

SANOFICONR Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

SANOFICONR Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sanofi Consumer Healthcare India Ltd63.7542.26
Sun Pharmaceutical Industries Ltd36.966.020.95%
Cipla Ltd22.734.471.08%
Torrent Pharmaceuticals Ltd56.2315.671.01%

SANOFICONR Stock Price Comparison

Compare SANOFICONR with any stock or ETF
Compare SANOFICONR with any stock or ETF
SANOFICONR
Loading...

SANOFICONR Shareholdings

SANOFICONR Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SANOFICONR Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SANOFICONR Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding60.40%15.09%10.39%4.53%9.59%

Sep 2024

Oct 2024

Dec 2024

Mar 2025

SANOFICONR Shareholding History

JunSepOctDec '24Mar6.03%5.22%4.87%4.42%4.53%

Mutual Funds Invested in SANOFICONR

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Sanofi Consumer Healthcare India Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.4137%0.47%-0.03%87/98 (-15)
1.2707%0.50%-0.01%70/96 (-20)
0.9162%0.18%-0.01%210/242 (-4)

Compare 3-month MF holding change on Screener

SANOFICONR Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SANOFICONR stock

Looks like this stock is not in any smallcase yet.

SANOFICONR Events

SANOFICONR Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SANOFICONR has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

SANOFICONR Upcoming Dividends

No upcoming dividends are available

SANOFICONR Past Dividends

Cash Dividend

Ex DateEx DateApr 17, 2025

Final
Final | Div/Share: ₹55.00

Dividend/Share

55.00

Ex DateEx Date

Apr 17, 2025

SANOFICONR Stock News & Opinions

Spotlight
Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr

Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India ' a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, 'We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.' SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofi's global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra', DePURA', Avil', and Combiflam'. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Sanofi Consumer Healthcare India standalone net profit declines 20.26% in the March 2025 quarter

Net profit of Sanofi Consumer Healthcare India declined 20.26% to Rs 50.00 crore in the quarter ended March 2025 as against Rs 62.70 crore during the previous quarter ended March 2024. Sales declined 22.11% to Rs 172.60 crore in the quarter ended March 2025 as against Rs 221.60 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales172.60221.60 -22 OPM %37.0836.91 - PBDT68.8084.80 -19 PBT66.8083.90 -20 NP50.0062.70 -20 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Sanofi Consumer Healthcare India to convene board meeting

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Sanofi Consumer Healthcare India revises record date for final dividend

Sanofi Consumer Healthcare India has revised the record date from 28 April 2025 to 17 April 2025 for final dividend of Rs 55 per equity share of face value of Rs 10 each for the year ended 31 December 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sanofi Consumer Healthcare CFO Maithilee Mistry resigns

According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization. In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role. His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations. Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce. Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24. The counter shed 0.85% to Rs 4,740.15 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sanofi Consumer Healthcare India AGM scheduled

Sanofi Consumer Healthcare India announced that the 2nd Annual General Meeting(AGM) of the company will be held on 5 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sanofi Consumer posts PAT of Rs 46 crore in Q3

Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY). Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY. Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce. The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Board of Sanofi Consumer Healthcare India recommends final dividend

Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on , inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter

Net profit of Sanofi Consumer Healthcare India declined 1.56% to Rs 44.30 crore in the quarter ended December 2024 as against Rs 45.00 crore during the previous quarter ended December 2023. Sales rose 6.75% to Rs 170.70 crore in the quarter ended December 2024 as against Rs 159.90 crore during the previous quarter ended December 2023. For the full year,net profit rose 9.83% to Rs 181.00 crore in the year ended December 2024 as against Rs 164.80 crore during the previous year ended December 2023. Sales rose 37.89% to Rs 724.50 crore in the year ended December 2024 as against Rs 525.40 crore during the previous year ended December 2023. ParticularsQuarter EndedYear EndedDec. 2024Dec. 2023% Var.Dec. 2024Dec. 2023% Var. Sales170.70159.90 7 724.50525.40 38 OPM %36.3839.46 -37.3541.66 - PBDT66.7063.90 4 279.70223.00 25 PBT65.7062.40 5 275.20221.00 25 NP44.3045.00 -2 181.00164.80 10 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Sanofi Consumer Healthcare India to declare Quarterly Result

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 20 February 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Sanofi Consumer Healthcare India Ltd (SANOFICONR) today?

    The share price of SANOFICONR as on 23rd May 2025 is ₹5009.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Sanofi Consumer Healthcare India Ltd (SANOFICONR) share?

    The past returns of Sanofi Consumer Healthcare India Ltd (SANOFICONR) share are
    • Past 1 week: 1.36%
    • Past 1 month: 2.82%
    • Past 3 months: 7.57%
    • Past 6 months: 4.60%
    • Past 1 year: 3.89%
    • Past 3 years: N/A%
    • Past 5 years: 2.17%

  3. What are the peers or stocks similar to Sanofi Consumer Healthcare India Ltd (SANOFICONR)?
  4. What is the market cap of Sanofi Consumer Healthcare India Ltd (SANOFICONR) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi Consumer Healthcare India Ltd (SANOFICONR) is ₹11537.88 Cr as of 23rd May 2025.

  5. What is the 52 week high and low of Sanofi Consumer Healthcare India Ltd (SANOFICONR) share?

    The 52-week high of Sanofi Consumer Healthcare India Ltd (SANOFICONR) is ₹5375 and the 52-week low is ₹4211.55.

  6. What is the PE and PB ratio of Sanofi Consumer Healthcare India Ltd (SANOFICONR) stock?

    The P/E (price-to-earnings) ratio of Sanofi Consumer Healthcare India Ltd (SANOFICONR) is 63.75. The P/B (price-to-book) ratio is 42.26.

  7. Which sector does Sanofi Consumer Healthcare India Ltd (SANOFICONR) belong to?

    Sanofi Consumer Healthcare India Ltd (SANOFICONR) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Sanofi Consumer Healthcare India Ltd (SANOFICONR) shares?

    You can directly buy Sanofi Consumer Healthcare India Ltd (SANOFICONR) shares on Tickertape. Simply sign up, connect your demat account and place your order.